Supreme Court Keeps Mifepristone Access Open

If you’re wondering whether the pill that accounts for roughly half of all abortions in the U.S. is suddenly harder to get because a federal appeals court said it was, the answer is no. Not yet.

The Supreme Court kept the door open.

On Thursday, the justices issued an order preserving access to mifepristone while the underlying lawsuit plays out. This means women can still pick up the drug at pharmacies or have it mailed to them without an in-person doctor’s visit. That status quo holds at least until next year, assuming the case doesn’t get tied up in further appeals.

Let’s look at the players. The court granted emergency requests from Danco Laboratories and GenBioPro, the makers of the drug. They were fighting a lower-court ruling that would have forced women to see a doctor in person and stopped mail delivery. The Food and Drug Administration, which approved mifepristone in 2000, dropped the in-person visit requirement five years ago. The Supreme Court just put that change on ice for now.

The dissent tells a different story, one rooted in profit and politics. Justices Clarence Thomas and Samuel Alito disagreed. Thomas wrote that these two companies aren’t entitled to relief just to save their "lost profits from their criminal enterprise." He’s referring to the Comstock Act, a 19th-century law banning the mailing of abortion drugs. Thomas argues that mailing the pills violates this old statute, which has largely gone unenforced.

Alito, who wrote the opinion overturning Roe v. Wade, agreed the state of Louisiana is winning its battle. Louisiana filed the lawsuit to roll back FDA rules, claiming the current policy undermines their state abortion ban. They argue that medical providers and private organizations are mailing pills directly to women in Louisiana, bypassing the ban. Alito noted that Danco and GenBioPro are "obviously aware of what is going on yet nevertheless supply the drug and reap profits from its felonious use in Louisiana."

This isn’t just a legal technicality. It’s a pressure point for anti-abortion groups who are frustrated with the Trump administration. They’ve been pushing the FDA to move faster on a review they hope will restrict mifepristone further, specifically by blocking telehealth prescribing. The administration says the work takes time. The groups say it takes too long.

That tension recently led to the resignation of FDA Commissioner Marty Makary. He stepped down after months of criticism from Trump’s political allies, including abortion opponents who blamed him for the slow pace of the mifepristone review. Susan B. Anthony Pro-Life America and similar groups had called for his head, arguing that the delay was a failure of leadership.

For context, this is the latest abortion controversy the Court has tackled since its conservative majority overturned Roe four years ago. That decision allowed more than a dozen states to effectively ban abortion outright. Louisiana’s lawsuit is an attempt to use the FDA’s own rules against the agency, claiming that the federal government’s approval of the drug undermines state bans.

The state questions the safety of the drug, which has repeatedly been deemed safe and effective by FDA scientists. Lower courts concluded that Louisiana is likely to prevail in this specific legal argument, which is why the Supreme Court’s intervention was necessary to keep the supply chain moving while the judges decide.

So the local impact is clear: the supply chain remains intact for now. You can still get the pill. You can still have it mailed. But the clock is ticking on the FDA review. If the administration moves faster on the restrictions anti-abortion groups want, the next ruling could change how you get the drug. Until then, the status quo holds. The makers keep selling. The patients keep taking. The courts keep arguing.